PubRank

Robert F Reilly

Author PubWeight™ 33.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013 7.29
2 Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006 1.98
3 What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 2007 1.60
4 Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral arterial segments: the COBRA trial. J Am Coll Cardiol 2012 1.43
5 Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012 1.42
6 Rhabdomyolysis: a review, with emphasis on the pediatric population. Pediatr Nephrol 2010 1.08
7 Unfractionated heparin for hemodialysis: still the best option. Semin Dial 2010 1.07
8 Association of urinary sodium/potassium ratio with blood pressure: sex and racial differences. Clin J Am Soc Nephrol 2011 1.06
9 Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 2008 1.02
10 Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 2010 0.98
11 Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 2011 0.96
12 Hereditary etiologies of hypomagnesemia. Nat Clin Pract Nephrol 2008 0.94
13 Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol 2008 0.89
14 Heparin-induced thrombocytopenia: a renal perspective. Nat Rev Nephrol 2009 0.88
15 Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Semin Dial 2003 0.87
16 Non-pharmacological aspects of blood pressure management: what are the data? Kidney Int 2011 0.85
17 Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease. Semin Dial 2008 0.84
18 Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection. Nephrology (Carlton) 2005 0.83
19 Vascular access surveillance: evaluation of combining dynamic venous pressure and vascular access blood flow measurements. Am J Nephrol 2003 0.83
20 Spondylodiscitis in a patient on chronic hemodialysis. Nat Rev Nephrol 2011 0.81
21 Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 2011 0.80
22 Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol 2012 0.80
23 Primary care approach to proteinuria. J Am Board Fam Med 2008 0.79
24 Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology (Carlton) 2006 0.78
25 Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol 2010 0.77
26 Gadolinium and nephrogenic systemic fibrosis: have we overreacted? Semin Dial 2011 0.76
27 Risk factors: filling in the gap. Nat Rev Nephrol 2012 0.75
28 Anticoagulation and continuous renal replacement therapy. Semin Dial 2006 0.75
29 Are calcium-based phosphate binders ever preferable in dialysis patients? Semin Dial 2014 0.75
30 Does the risk exceed the benefit for anticoagulation in end-stage renal disease patients with nonrheumatic atrial fibrillation? Semin Dial 2011 0.75
31 Hungry bone syndrome. Curr Opin Nephrol Hypertens 2017 0.75